US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Femasys Inc.

< Previous 1 2 3 Next >
News headline image
Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Regains Compliance with Nasdaq Listing Requirements
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Announces Third Quarter Financial Results for 2025
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Partners with Medical Electronic Systems to Launch FemSperm™ Analysis Kit for use with FemaSeed
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
< Previous 1 2 3 Next >